Aytu BioPharma, Inc. (AYTU)
USD 1.06
(0.95%)
USD 1.06
(0.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 54.58 Million USD | -18.08% |
| 2023 | 66.63 Million USD | 27.44% |
| 2022 | 52.28 Million USD | 79.05% |
| 2021 | 29.2 Million USD | 45.43% |
| 2020 | 20.07 Million USD | 292.3% |
| 2019 | 5.11 Million USD | 218.02% |
| 2018 | 1.6 Million USD | -10.8% |
| 2017 | 1.8 Million USD | 12.39% |
| 2016 | 1.6 Million USD | 824.36% |
| 2015 | 173.67 Thousand USD | 194.72% |
| 2014 | 58.92 Thousand USD | 17.86% |
| 2013 | 50 Thousand USD | 2757.14% |
| 2012 | 1750.00 USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 1750.00 USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 11.69 Million USD | -27.83% |
| 2024 Q1 | 14.78 Million USD | -20.36% |
| 2024 Q4 | 11.9 Million USD | 1.82% |
| 2024 Q2 | 16.2 Million USD | 9.6% |
| 2023 Q4 | 18.56 Million USD | 45.68% |
| 2023 Q3 | 12.74 Million USD | -26.31% |
| 2023 FY | 66.63 Million USD | 27.44% |
| 2023 Q1 | 18.03 Million USD | 21.49% |
| 2023 Q2 | 17.29 Million USD | -4.1% |
| 2022 Q3 | 12.68 Million USD | 3.15% |
| 2022 Q4 | 14.84 Million USD | 17.0% |
| 2022 FY | 52.28 Million USD | 79.05% |
| 2022 Q2 | 12.29 Million USD | -1.26% |
| 2022 Q1 | 12.45 Million USD | 10.24% |
| 2021 Q1 | 9.7 Million USD | -5.71% |
| 2021 Q4 | 11.29 Million USD | 5749.08% |
| 2021 Q2 | 9.14 Million USD | -5.69% |
| 2021 Q3 | -200.01 Thousand USD | -102.19% |
| 2021 FY | 29.2 Million USD | 45.43% |
| 2020 Q4 | 10.28 Million USD | 67.08% |
| 2020 FY | 20.07 Million USD | 292.3% |
| 2020 Q3 | 6.15 Million USD | 139.67% |
| 2020 Q1 | 1.06 Million USD | -0.22% |
| 2020 Q2 | 2.56 Million USD | 141.44% |
| 2019 Q2 | 1.26 Million USD | 24.37% |
| 2019 Q1 | 1.02 Million USD | 49.3% |
| 2019 Q4 | 1.06 Million USD | -39.44% |
| 2019 FY | 5.11 Million USD | 218.02% |
| 2019 Q3 | 1.76 Million USD | 38.67% |
| 2018 Q1 | 788.79 Thousand USD | 62.24% |
| 2018 FY | 1.6 Million USD | -10.8% |
| 2018 Q4 | 683.9 Thousand USD | 229.08% |
| 2018 Q3 | -529.83 Thousand USD | -179.6% |
| 2018 Q2 | 665.58 Thousand USD | -15.62% |
| 2017 Q3 | 569.56 Thousand USD | 134.67% |
| 2017 Q2 | 242.7 Thousand USD | -52.04% |
| 2017 Q4 | 486.18 Thousand USD | -14.64% |
| 2017 FY | 1.8 Million USD | 12.39% |
| 2017 Q1 | 506.07 Thousand USD | -16.0% |
| 2016 Q3 | 327.63 Thousand USD | 45.4% |
| 2016 Q4 | 602.45 Thousand USD | 83.88% |
| 2016 Q1 | 450.06 Thousand USD | 379.16% |
| 2016 Q2 | 225.32 Thousand USD | -49.93% |
| 2016 FY | 1.6 Million USD | 824.36% |
| 2015 Q1 | 27.35 Thousand USD | 2635.8% |
| 2015 Q4 | 93.92 Thousand USD | 294.17% |
| 2015 Q3 | 23.82 Thousand USD | 0.0% |
| 2015 Q2 | 23.82 Thousand USD | -12.9% |
| 2015 FY | 173.67 Thousand USD | 194.72% |
| 2014 Q1 | -3500.00 USD | -300.0% |
| 2014 Q2 | - USD | 100.0% |
| 2014 Q4 | 1000.00 USD | -92.0% |
| 2014 Q3 | 12.5 Thousand USD | 0.0% |
| 2014 FY | 58.92 Thousand USD | 17.86% |
| 2013 Q2 | - USD | -100.0% |
| 2013 FY | 50 Thousand USD | 2757.14% |
| 2013 Q4 | 1750.00 USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | 1750.00 USD | 0.0% |
| 2012 FY | 1750.00 USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | -100.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2010 Q1 | -1750.00 USD | -200.0% |
| 2010 Q2 | - USD | 100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | 1750.00 USD | 0.0% |
| 2009 Q4 | 1750.00 USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 FY | 1750.00 USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -83.47% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 83.265% |
| Journey Medical Corporation | 52.52 Million USD | -3.932% |
| Dynavax Technologies Corporation | 182.11 Million USD | 70.027% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 25.293% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 87.324% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 88.867% |
| PainReform Ltd. | -15 Thousand USD | 364006.667% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -1202.405% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -554.573% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -554.573% |
| SCYNEXIS, Inc. | 124.51 Million USD | 56.162% |
| Silver Spike Investment Corp. | 8.1 Million USD | -573.685% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -9753.584% |
| Alpha Teknova, Inc. | 10.29 Million USD | -430.167% |
| Alvotech | -69.42 Million USD | 178.629% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 82.121% |
| Bright Green Corporation | -237.01 Thousand USD | 23130.513% |
| Embecta Corp. | 749.9 Million USD | 92.721% |
| Safety Shot Inc | -74.45 Thousand USD | 73412.113% |
| Procaps Group, S.A. | 239.56 Million USD | 77.215% |
| Cosmos Health Inc. | 4.34 Million USD | -1154.975% |
| Theratechnologies Inc. | 62.12 Million USD | 12.141% |
| Harrow Health, Inc. | 90.55 Million USD | 39.719% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -1050.39% |
| Biofrontera Inc. | 16.62 Million USD | -228.297% |
| DURECT Corporation | 6.83 Million USD | -699.092% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 89.578% |
| Cronos Group Inc. | 6.99 Million USD | -680.816% |
| OptiNose, Inc. | 62.35 Million USD | 12.458% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 87.627% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 18115.182% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -1687.26% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 82.38% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -911.879% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -63.012% |
| Radius Health, Inc. | 307.71 Million USD | 82.261% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -441.642% |
| ProPhase Labs, Inc. | 16.23 Million USD | -236.141% |
| Phibro Animal Health Corporation | 312.48 Million USD | 82.532% |
| Procaps Group S.A. | 239.56 Million USD | 77.215% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -4092.473% |
| Viatris Inc. | 6.43 Billion USD | 99.152% |
| Rockwell Medical, Inc. | 8.7 Million USD | -527.137% |
| SIGA Technologies, Inc. | 122.09 Million USD | 55.291% |
| Tilray Brands, Inc. | 223.35 Million USD | 75.56% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -30.432% |
| Shineco, Inc. | 882.16 Thousand USD | -6087.71% |
| PetIQ, Inc. | 252.74 Million USD | 78.402% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 7421.202% |
| Incannex Healthcare Limited | 12 Thousand USD | -454783.333% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 97.045% |
| Alimera Sciences, Inc. | 61.17 Million USD | 10.763% |
| Assertio Holdings, Inc. | 125.04 Million USD | 56.348% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 801538.849% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -732.611% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2364.814% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -101.298% |
| Hempacco Co., Inc. | -1.21 Million USD | 4589.597% |
| Talphera, Inc. | -4.89 Million USD | 1215.138% |
| Alvotech | -69.42 Million USD | 178.629% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 75.376% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 92.307% |
| Currenc Group, Inc. | 17.35 Million USD | -214.502% |
| Kamada Ltd. | 52.59 Million USD | -3.79% |
| Indivior PLC | 907 Million USD | 93.982% |
| Evoke Pharma, Inc. | 4.97 Million USD | -996.379% |
| Flora Growth Corp. | 17.73 Million USD | -207.735% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 2364.814% |
| Evolus, Inc. | 140.52 Million USD | 61.156% |
| HUTCHMED (China) Limited | 453.55 Million USD | 87.965% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 84.131% |
| Akanda Corp. | 111.44 Thousand USD | -48878.457% |